Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Dezember 2020 07:00 ET | Quelle: Newscope Capital Corporation

PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease

TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...
08. Dezember 2020 07:00 ET | Quelle: Newscope Capital Corporation

PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson’s Disease

TORONTO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty...
01. Dezember 2020 07:00 ET | Quelle: Newscope Capital Corporation

PharmaTher Expands Research Partnership with University Health Network For Development of Digital Therapeutics Platform

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences...
24. November 2020 11:09 ET | Quelle: Newscope Capital Corporation

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the...
18. November 2020 07:00 ET | Quelle: Newscope Capital Corporation

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the...
16. November 2020 07:00 ET | Quelle: Newscope Capital Corporation

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent for Novel Use of Psilocybin to Treat Cancer

TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher” or the “Company”) (CSE: PHRM) and a specialty life sciences...
11. November 2020 07:00 ET | Quelle: Newscope Capital Corporation

Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor

TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
29. Oktober 2020 07:00 ET | Quelle: Newscope Capital Corporation

Leading Parkinson’s Researcher Dr. Robert A. Hauser Joins Pharmather as Scientific Advisor

TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
27. Oktober 2020 07:00 ET | Quelle: Newscope Capital Corporation

Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain

TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...
22. Oktober 2020 07:00 ET | Quelle: Newscope Capital Corporation

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

TORONTO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences...

Vorherige Seite

Nächste Seite